CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 135 filers reported holding CRISPR THERAPEUTICS AG in Q1 2018. The put-call ratio across all filers is 3.59 and the average weighting 1.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $20,190,000 | -32.3% | 266,430 | 0.0% | 0.57% | -23.3% |
Q3 2021 | $29,822,000 | -30.9% | 266,430 | 0.0% | 0.74% | -32.2% |
Q2 2021 | $43,132,000 | +32.9% | 266,430 | 0.0% | 1.10% | +13.2% |
Q1 2021 | $32,464,000 | -20.4% | 266,430 | 0.0% | 0.97% | -20.0% |
Q4 2020 | $40,793,000 | +83.1% | 266,430 | 0.0% | 1.21% | +21.1% |
Q3 2020 | $22,284,000 | +13.8% | 266,430 | 0.0% | 1.00% | -13.9% |
Q2 2020 | $19,580,000 | +73.3% | 266,430 | 0.0% | 1.16% | -3.3% |
Q1 2020 | $11,299,000 | +15.8% | 266,430 | +21.1% | 1.20% | +1.1% |
Q3 2018 | $9,757,000 | -24.5% | 220,000 | 0.0% | 1.19% | -34.4% |
Q2 2018 | $12,927,000 | +109.5% | 220,000 | +63.0% | 1.81% | +66.6% |
Q1 2018 | $6,171,000 | – | 135,000 | – | 1.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |